NKD Company Overview, Contact Details & Competitors

Q: What is NKD's official website and social media links?

NKD's official website is nkd.co.uk. NKD has social profiles on LinkedIn.

Q: How many employees does NKD have currently?

NKD has approximately 207 employees.

Q: What technology does NKD use?

NKD's tech stack includes jQuery UI, Cookie Notice, Open Graph, prettyPhoto, Yoast SEO.

Q: What is NKD's NAICS code?

NKD's NAICS code is 6114 (Business Schools and Computer and Management Training).

Insights

Gathering insights about NKD…

Similar companies to NKD

NKD Tech Stack

NKD uses 8 technology products and services including Salesforce, Font Awesome, jQuery UI, and more. Explore NKD's tech stack below.

Salesforce
Customer Relationship Management
Font Awesome
Font Scripts
jQuery UI
Javascript Libraries
jQuery
Javascript Libraries
Salesforce Marketing Cloud Account Engagement
Marketing Automation
Priority Hints
Performance
Timesheets
Time Tracking
IONOS
Web Hosting

Media & News

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes DANBURY, Conn.
Jun 05, 2026 | www.globenewswire.com
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
Jun 05, 2026 | www.globenewswire.com
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
Jun 03, 2026 | www.globenewswire.com
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
MannKind gains FDA approval for Afrezza pediatric use, expanding its differentiated inhaled insulin therapy to children aged 6+ with type 1 or 2 diabetes. I see Afrezza's pediatric label extension as a durable growth inflection, targeting a concentrated 360,000-patient U.S. base and 30,000 annual inflow, with an efficient commercial strategy. MNKD estimates a 23–37% pediatric market share, translating to a $300–500 million revenue opportunity, with gradual adoption expected to accelerate meaningfully by 4Q26 and into 2027.
Jun 02, 2026 | seekingalpha.com
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin's label into children and adolescents.
May 30, 2026 | www.marketbeat.com
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
May 29, 2026 | seekingalpha.com
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that management will host a conference call to discuss the recent FDA approval of Afrezza® for use in children and adolescents aged 6 and older living with diabetes at 4:30 p.m. Eastern on Friday, May 29, 2026. Presenting from the Company will be its Chief Executive Officer, Michael Castagna, PharmD and Kevin Kaiserman, MD, Senior Vice President, Therapeutic Area Head-Diabetes.
May 29, 2026 | www.globenewswire.com

NKD's Email Address Formats

NKD uses at least 1 format(s):

NKD Email Formats	Example	Percentage
First@nkd.co.uk	John@nkd.co.uk	75%
First.Last@nkd.co.uk	John.Doe@nkd.co.uk	14%
FirstLast@nkd.co.uk	JohnDoe@nkd.co.uk	8%
Last@nkd.co.uk	Doe@nkd.co.uk	3%

Frequently Asked Questions

Where is NKD's headquarters located?

NKD's main headquarters is located at 1 Finsbury Avenue Nkd Storey London, England ec2m 2pf United Kingdom. The company has employees across 6 continents, including EuropeAsiaOceania.

What is NKD's stock symbol?

NKD is a publicly traded company; the company's stock symbol is MNKD.

What is NKD's official website and social media links?

NKD's official website is nkd.co.uk and has social profiles on LinkedIn.

What is NKD's SIC code NAICS code?

NKD's SIC code is 8299 - Schools and Educational Services, Not Elsewhere Classified NAICS code is 6114 - Business Schools and Computer and Management Training.

How many employees does NKD have currently?

As of May 2026, NKD has approximately 207 employees across 6 continents, including EuropeAsiaOceania. Key team members include Chief Executive Officer: M. J. F.Chief Operating Officer: A. S.Chief Financial Officer: B. M.. Explore NKD's employee directory with LeadIQ.

What industry does NKD belong to?

NKD operates in the Professional Training and Coaching industry.

What technology does NKD use?

NKD's tech stack includes SalesforceFont AwesomejQuery UIjQuerySalesforce Marketing Cloud Account EngagementPriority HintsTimesheetsIONOS.

What is NKD's email format?

NKD's email format typically follows the pattern of First@nkd.co.uk. Find more NKD email formats with LeadIQ.

When was NKD founded?

NKD was founded in 2005.

Insights

Similar companies to NKD

Takko Fashion

H&M

Primark

KIK

Forever 21

Deichmann

C&A China

New Yorker

Tchibo

Esprit

NKD Tech Stack

Media & News

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind At An Inflection Point: Pediatric Expansion Drives The Story

MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market

MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

NKD's Email Address Formats

Frequently Asked Questions

Where is NKD's headquarters located?

What is NKD's stock symbol?

What is NKD's official website and social media links?

What is NKD's SIC code NAICS code?

How many employees does NKD have currently?

What industry does NKD belong to?

What technology does NKD use?

What is NKD's email format?

When was NKD founded?

NKD

Company Overview

Media & News

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?